flag flag  

author = "Frere, Pascale"

Found 23 documents, displaying page 1 of 3

Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion.

Description : We evaluated the ability of recombinant human erythropoietin (rHuEpo) therapy, given before high-dose therapy (HDT), to allow autologous peripheral blood stem cell transplantation (PBSCT) without red blood cell (RBC) transfusions. Eleven multiple myeloma patients underwent tandem HDT and autologous ...
Repository : ORBi (University of Liège)
Language(s) : English

Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation.

Description : Immune reconstitution may be delayed after CD34-selected compared with unmanipulated autologous peripheral blood stem cell transplantation (PBSCT), resulting in a theoretically increased risk of infections. In a case-control matched study we compared the incidence of infection in 25 recipients of CD...
Repository : ORBi (University of Liège)
Language(s) : English

Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment.

Description : PURPOSE: Previous trials of recombinant human erythropoietin (rHuEpo) therapy after autologous hematopoietic stem cell transplantation have administered very high doses of i.v. rHuEpo starting on day 1 and continuing for 1-2 months until erythroid engraftment and have shown no benefit of rHuEpo ther...
Repository : ORBi (University of Liège)
Language(s) : English

Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation.

Description : On day 30 after autologous peripheral blood stem cell transplantation (PBSCT), 20 patients were randomized to receive either erythropoietin at a dose of 500 U/kg/week s.c. (Epo group) or no treatment (control group). After 3 weeks, hemoglobin (p<0.0001) and serum transferrin receptor (p<0.0001) conc...
Repository : ORBi (University of Liège)
Language(s) : English

Immunotherapie du cancer par minigreffe de cellules souches hematopoietiques. Nonmyeloablative stem cell transplantation as cancer immunotherapy

Description : Allogeneic hematopoietic stem cell transplantation (HSCT) is used for the treatment of selected haematological malignancies. Its curative potential is based on two different mechanisms, i.e. the conditioning regimen and the graft-versus-host immunologic reactions. However, because of its toxicity, i...
Repository : ORBi (University of Liège)
Language(s) : French

Found 23 documents, displaying page 1 of 3